纖溶酶原激活物抑制因子1(PAI1)單克隆抗體
Monoclonal Antibody to Plasminogen Activator Inhibitor 1 (PAI1)
SERPINE1; PLANH1; Serpin Peptidase Inhibitor Clade E Member 1; Nexin,Plasminogen Activator Inhibitor Type 1 Serpin E1; Endothelial plasminogen activator inhibitor
- 編號(hào)UMAA532Hu27
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源單抗制備
- 宿主小鼠
- 效價(jià)(克隆號(hào))D4
- Ig亞型 IgG1 Kappa
- 純化方式蛋白A + 蛋白G親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原 RPA532Hu02-纖溶酶原激活物抑制因子1(PAI1)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度1mg/ml
- 且適物種Sus scrofa; Porcine (Pig，豬)
- 應(yīng)用IHC
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 330 ¥ 771 ¥ 1101 ¥ 2753 ¥ 11010
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
DAB staining on IHC-P; Sample: Porcine Colon Tissue Primary Ab: 20μg/ml Mouse Anti-Human PAI1 Antibody Control: Used PBS instead of primary antibody Second Ab: 2μg/ml HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
-
DAB staining on IHC-P;
Sample: Porcine Kidney Tissue
Primary Ab: 20μg/ml Mouse Anti-Human PAI1 Antibody
Control: Used PBS instead of primary antibody
Second Ab: 2μg/ml HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19)
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)PAI1的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別PAI1。
用法
Western blotting: 0.01-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA532Hu02 | 纖溶酶原激活物抑制因子1(PAI1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UEPA532Hu61 | 纖溶酶原激活物抑制因子1(PAI1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA532Hu01 | 纖溶酶原激活物抑制因子1(PAI1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPA532Hu61 | 纖溶酶原激活物抑制因子1(PAI1)活性蛋白 | Cell?culture;?Activity?Assays. |
| UPAA532Hu01 | 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體 | WB; IHC |
| UPAA532Hu02 | 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體 | WB; IHC |
| ULAA532Hu71 | 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| ULAA532Hu81 | 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| UMAA532Hu22 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC/IF; FCM |
| UMAA532Hu24 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC |
| UMAA532Hu27 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | IHC |
| UMAA532Hu29 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | ICC/IF |
| UMAA532Hu25 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | ICC/IF |
| UMAA532Hu21 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC/IF |
| UMAA532Hu26 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB |
| UMAA532Hu28 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; ICC/IF |
| UMAA532Hu23 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC |
| UFAA532Hu04 | 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | FCM |
| UFAA532Hu02 | 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | FCM |
| UFAA532Hu06 | 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | FCM |
| UFAA532Hu08 | 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | FCM |
| ULAA532Hu74 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體(生物素標(biāo)記) | WB |
| ULAA532Hu76 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| UMEA532Hu | 纖溶酶原激活物抑制因子1(PAI1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USEA532Hu | 纖溶酶原激活物抑制因子1(PAI1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCA532Hu | 纖溶酶原激活物抑制因子1(PAI1)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMA532Hu | 纖溶酶原激活物抑制因子1(PAI1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UPSA532Hu01 | 纖溶酶原激活物抑制因子1(PAI1)抗體對(duì) | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
| UKSA532Hu01 | 纖溶酶原激活物抑制因子1(PAI1)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Breast Cancer Research and Treatment | Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice [SpringerLink: f3w831267267p277] |
| Clin Appl Thromb Hemost. | Is There Any Association Between Thrombosis and Tissue Factor Pathway Inhibitor Levels in Patients With Vitamin D Deficiency? [Pubmed: 24203351] |
| Molecular Nutrition & Food Research | Trans‐fatty acid promotes thrombus formation in mice by aggravating antithrombogenic endothelial functions via Toll‐like receptors [PubMed: 25546502] |
| Archives of Physiology and Biochemistry | Activation of cardiac renin–angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder [Pubmed:26934364] |
| Naunyn-Schmiedeberg's Archives of Pharmacology | Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expression [pubmed:27447455] |
| Environmental toxicology and pharmacology | Combined oral contraceptive and nitric oxide synthesis inhibition synergistically causes cardiac hypertrophy and exacerbates insulin resistance in female rats. [pubmed:28376377] |
| Annals of Clinical & Laboratory Science | Alteration of Hemostatic Parameters in Patients with Different Levels of Subclinical Hypothyroidism and the Effect of L-thyroxine Treatment [pubmed:28249913] |
| Pharmacological reports | Anti-inflammatory and antithrombotic effects of nicotine exposure in oral contraceptive-induced insulin resistance are glucocorticoid-independent [pubmed:28349880] |
| Haematologica | Cytoprotective and pro-angiogenic functions of thrombomodulin are preserved in the C loop of the fifth epidermal growth factor-like domain [Pubmed:29903766] |
| Biomedicine & Pharmacotherapy | Puerarin prevents vascular endothelial injury through suppression of NF-κB activation in LPS-challenged human umbilical vein endothelial cells [Pubmed:29775893] |
| Archives of?Physical?Medicine?and Rehabilitation | Impact of Regular Physical Activity on Adipocytokines and Cardiovascular Characteristics in Spinal Cord–Injured Subjects [Pubmed:29548578] |
| Marine Drugs | Anticoagulant and Antithrombotic Properties in Vitro and in Vivo of a Novel Sulfated Polysaccharide from Marine Green Alga Monostroma nitidum [Pubmed: 31027312] |
| Experimental and Therapeutic Medicine | IKKβ regulates the expression of coagulation and fibrinolysis factors through the NF?κB canonical pathway in LPS?stimulated alveolar epithelial cells type II [Pubmed: 31572531] |
| Phytomedicine | Sodium aescinate significantly suppress postoperative peritoneal adhesion by inhibiting the RhoA/ROCK signaling pathway [Pubmed: 32120245] |
| Sci Rep | Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis [Pubmed:35013379] |
| Phytomedicine | Multi-omics analysis reveals the mechanisms of action and therapeutic regimens of traditional Chinese medicine, Bufei Jianpi granules: Implication for COPD drug?… [Pubmed:35121390] |
留言咨詢
